ICD Code R87.810
ICD code R87.810 is used to indicate a positive cervical high risk human papillomavirus (HPV) DNA test result in medical records.
Boost patient experience and your bottom line by automating patient cost estimates, payer underpayment detection, and contract optimization in one place.
What is ICD diagnosis code R87.810
ICD code R87.810 is a positive test result for high-risk human papillomavirus (HPV) DNA in the cervix.
When to use ICD code R87.810
1. Patient has undergone cervical HPV DNA testing
2. Laboratory results indicate a positive finding for high-risk HPV types
3. No evidence of cervical cancer or precancerous lesions at the time of testing
4. Patient may be asymptomatic or present for routine cervical cancer screening
5. Test performed as part of follow-up for abnormal cervical cytology or as co-testing with Pap smear
Billable CPT codes for ICD code R87.810
Relevant CPT codes for ICD code R87.810 include:
- 87624: Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), high-risk types
- 87625: Infectious agent detection by nucleic acid (DNA or RNA); Human Papillomavirus (HPV), types 16 and 18 only
- 88142: Cytopathology, cervical or vaginal (Pap smear), collected in preservative fluid, automated thin layer preparation; manual screening under physician supervision
- 88175: Cytopathology, cervical or vaginal (Pap smear), collected in preservative fluid, automated thin layer preparation; screening by automated system, with manual rescreening
These CPT codes are commonly used in conjunction with ICD code R87.810.
Are you being underpaid for encounters with R87.810
Schedule a demo to see how MD Clarity’s RevFind software can read your contracts and automatically detect underpayments for CPT codes related to ICD code R87.810. Discover how easy it is to ensure you’re being paid accurately for every service—book your personalized walkthrough today.
Get paid in full by bringing clarity to your revenue cycle
Related ICD Codes
Subscribe to the

Healthcare Clarified newsletter
Get the latest insights on RCM and healthcare policy in your inbox
